SVRA Key Statistics, Chart & Performance
The current stock price of SVRA is 6.29 USD. In the past month the price increased by 46.28%. In the past year, price increased by 87.2%.
SVRA Latest News, Press Relases and Analysis
SVRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About SVRA
Company Profile
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Company Info
SAVARA INC
6836 Bee Cave Road, Building 3, Suite 201
Austin TEXAS 78746 US
CEO: Matthew Pauls
Employees: 59
Phone: 151285113796
SAVARA INC / SVRA FAQ
Can you describe the business of SAVARA INC?
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Can you provide the latest stock price for SAVARA INC?
The current stock price of SVRA is 6.29 USD. The price increased by 17.35% in the last trading session.
Does SVRA stock pay dividends?
SVRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SVRA stock?
SVRA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is SAVARA INC (SVRA) stock traded?
SVRA stock is listed on the Nasdaq exchange.
What do analysts say about SAVARA INC (SVRA) stock?
14 analysts have analysed SVRA and the average price target is 10.52 USD. This implies a price increase of 67.23% is expected in the next year compared to the current price of 6.29.
What is the next earnings date for SVRA stock?
SAVARA INC (SVRA) will report earnings on 2026-03-25, after the market close.
SVRA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SVRA. When comparing the yearly performance of all stocks, SVRA is one of the better performing stocks in the market, outperforming 96.4% of all stocks.
SVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SVRA. The financial health of SVRA is average, but there are quite some concerns on its profitability.
SVRA Financial Highlights
Over the last trailing twelve months SVRA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -23.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.03% | ||
| ROE | -122.48% | ||
| Debt/Equity | 0.32 |
SVRA Forecast & Estimates
14 analysts have analysed SVRA and the average price target is 10.52 USD. This implies a price increase of 67.23% is expected in the next year compared to the current price of 6.29.